Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T-cell therapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
ChiCTR1800015817Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UCD19 CAR-T in non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: PET-CT assessment, Safety and 1 more. Started Apr 2017; status: recruiting.
02
Drugs
UCD19 CAR-T
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR1800015817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015817.